These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15382890)

  • 1. Computational titration analysis of a multiprotic HIV-1 protease-ligand complex.
    Spyrakis F; Fornabaio M; Cozzini P; Mozzarelli A; Abraham DJ; Kellogg GE
    J Am Chem Soc; 2004 Sep; 126(38):11764-5. PubMed ID: 15382890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
    Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
    Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
    Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
    Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
    J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.
    Louis JM; Dyda F; Nashed NT; Kimmel AR; Davies DR
    Biochemistry; 1998 Feb; 37(8):2105-10. PubMed ID: 9485357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
    Lu Y; Yang CY; Wang S
    J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
    Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
    Zoete V; Michielin O; Karplus M
    J Mol Biol; 2002 Jan; 315(1):21-52. PubMed ID: 11771964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
    Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
    J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
    Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity in modeling and understanding protonation states: computational titration of HIV-1-protease-inhibitor complexes.
    Tripathi A; Fornabaio M; Spyrakis F; Mozzarelli A; Cozzini P; Kellogg GE
    Chem Biodivers; 2007 Nov; 4(11):2564-77. PubMed ID: 18027371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural parameterization of the binding enthalpy of small ligands.
    Luque I; Freire E
    Proteins; 2002 Nov; 49(2):181-90. PubMed ID: 12210999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
    Li D; Liu MS; Ji B; Hwang K; Huang Y
    J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
    Brynda J; Rezacova P; Fabry M; Horejsi M; Stouracova R; Sedlacek J; Soucek M; Hradilek M; Lepsik M; Konvalinka J
    J Med Chem; 2004 Apr; 47(8):2030-6. PubMed ID: 15056001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region.
    Geller M; Miller M; Swanson SM; Maizel J
    Proteins; 1997 Feb; 27(2):195-203. PubMed ID: 9061783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
    Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
    J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations.
    Verkhivker GM
    Pac Symp Biocomput; 1996; ():638-52. PubMed ID: 9390264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
    Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
    J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition and catalytic mechanism of HIV-1 aspartic protease.
    Silva AM; Cachau RE; Sham HL; Erickson JW
    J Mol Biol; 1996 Jan; 255(2):321-46. PubMed ID: 8551523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.